Thought leadership
Essays on translation economics, operating model choices, and institutional design — written for founders, partners, and investors assessing women's health ventures seriously.
These pieces document reasoning and standards for the proposed platform. They may be revised as governance and program settings are confirmed; they are not marketing collateral.
For founders
Start with why women's health needs specialist translation infrastructure, then how stage-gated support works, then navigating the regulatory landscape.
For investors
Start with the global investment landscape, then the economic case, then what successful translation has in common.
For partners
Start with why institutions matter, then what the MRFF Incubator means, then the Australian research landscape.
Featured
Markets
A 236-page history from Stifel's healthcare investment banking group lands as a bull thesis for the category Women's Health Foundry is built to serve. The signal matters more than the specifics — and Volume III, due later in 2026, is the one to watch.
Read essayIdeas
5 min read
For all our talk of productivity and sovereign capability, we are overlooking one of the smartest investments we can make. Anthony Liveris argues that treating women's health as core economic policy could unlock national capability.
Read essayAustralia
10 min read
Australia has world-class research programs in reproductive biology, maternal health, and hormonal medicine. The challenge is converting that science into ventures that reach patients — and the infrastructure gap that sits between discovery and adoption.
Read essayPolicy
8 min read
The MRFF's BioMedTech Incubator program represents a structural intervention: government co-investment in the translation layer between research and commercial viability. Here is why that matters for women's health.
Read essayCase studies
7 min read
The most useful lessons in women's health translation come from looking closely at how certain companies moved from promising science into credible commercial pathways. The pattern is consistent: success depends on a tighter fit between evidence, clinical adoption, reimbursement logic and operating capability.
Read essayMarkets
8 min read
After years of being dismissed as niche, women's health is attracting serious capital globally. Understanding where the money is going — and where it is not — reveals the opportunity for a specialist Australian platform.
Read essayEcosystem
10 min read
Women's health is often treated as though it can move through the same translation pathways as any other category, with only more capital or attention required. In practice, the hardest questions arise before capital is ready to engage — in study design, endpoint selection, regulatory framing, and clinical adoption.
Read essayEconomics
7 min read
Women's health is not a social good separate from economic policy. When chronic conditions go unaddressed, the costs show up in workforce participation, productivity, and downstream healthcare spend.
Read essayOperating model
7 min read
De-risking is not a slogan. It is a sequence of decisions that make the next failure mode cheaper — without turning innovation teams into administrators.
Read essayRegulation
8 min read
The TGA, PBAC, and MSAC pathways shape which women's health innovations reach patients and which stall. Understanding the regulatory landscape early is not optional — it is a core translation competency.
Read essayInstitutions
6 min read
National platforms succeed when they strengthen — not bypass — universities, health services, industry, and investors. Shared milestones and governance-aware collaboration are how that works in practice.
Read essay